Bot Chart, page-2553

I am back in at 11.5c, the sell off seems overdone and nearly done.

If you ignore the issue with the effectiveness of the US vehicle then nothing has changed with BOT so when adding that back to the equation the question is whether the US vehicle anomaly invalidates CBD/Permetrex completely, slightly or not at all.

No doubt the market has spoken and think this is a big step backwards but the phase 2 study has shown that the safety profile is market leading and the efficacy is equivalent to existing topical acne treatments so on that measure you can see why BOT are moving ahead with phase 3 results.

Sentiment will be dragged upward from here as the company continues it's march towards commercialisation with the FDA meeting then preparation for phase 3 studies but plenty of other side shows to keep news flow bubbling along (dermatitis, anti-microbial etc).